Article
Glycophorin A mutations and risk of secondary leukaemia in patients treated for childhood acute lymphoblastic leukaemia.
British journal of haematology - 1 Apr 1996
Boyse J, Hewitt M, Mott M G
Abstract excerpt
Survivors of child acute lymphoblastic leukaemia (ALL) have a higher than expected risk of developing secondary acute myeloid leukaemia (AML). The glycophorin A (GPA) mutation assay measures the frequency of variant NO and NN erythrocytes in MN heterozygotes. A raised variant frequency (Vf) has been shown in patients treated with chemotherapy known to be at risk of secondary leukaemia. ALL patients were...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
